Autopsy report · NCT00027521

Electroporation Therapy With Bleomycin in Treating Patients With Pancreatic Cancer

“Program terminated”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 1

Sponsor

Ichor Medical Systems Incorporated

Sponsor type

Industry

Conditions

Pancreatic Cancer

Interventions

bleomycin sulfate; electroporation therapy

Participants

0

Trials that died the same way

• Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy
  “Development program terminated” (82% match in meaning)
• GALLANT 22 Tesaglitazar vs. Placebo
  “The development program has been terminated” (70% match in meaning)
• Comparison of Low-dose Epidural With Intravenous Narcotic Versus Intravenous Narcotic Alone
  “terminated by PI” (63% match in meaning)
• Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer
  “Program terminated due to lack of meaningful efficacy signal.” (59% match in meaning)
• Physician's Comfort Level and Satisfaction Study With The e2TM Collector Compared to the Spatula/CytoBrush Technique
  “Terminated for lack of resources to complete.” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.